One of the cancers of the modern age is a lymphoma. This text deals with the new method of treatment that has proved to be very efficient. Follicular lymphoma is a form of a non-Hodgkin's lymphoma. This type of lymphoma appears in almost 15% of all cases. A new drug that has been introduced in this text is called Bexxar, and a study on this drug was conducted. In the study, patients who weren’t previously treated from follicular lymphoma didn’t have a relapse after this. This new therapy is a combination of cancer-killing antibodies and radiation. The advantages of Bexxar are that the radiation isn’t so strong and the immunity system is able to undergo the therapy needed in order to destroy the cancer cells. Bexxar is given through transfusion and the antibodies give strength to the immune system to fight the cancer.
Researches and studies
Researcher Mark Kaminski, MD, professor of internal medicine at the University Of Michigan Comprehensive Cancer Center in Ann Arbor has nothing but words of appraisal for this new treatment. The pros of Bexxar is that it has very little toxicity contrary to the orthodox way of treatment, which consists of a high level of toxicity, and which while destroying the cancer, also destroys the immune system of the patient.
FDA approved Bexxar in 2003 and it has been used since then in patients who didn’t responds to the regular ways of treatment of lymphoma cancer. In the study that was conducted, participants were 76 people who were in the advanced stage of follicular lymphoma and they weren’t subjected to any form of treatment. During the period of 8 years, they were given Bexxar treatment for one week in a month and their treatment has been monitored. The results were extraordinary: 95% of the patients involved responded to the treatment, and in 75% of the cancer disappeared completely.
How does Bexxar functions?
Bexxar is something like a missile and when it is given through infusion, it looks for malignant cells. Once it finds them, it destroys them, leaving the healthy tissue. Other doctors ensure us that this new drug is a second chance for people who suffer from follicular lymphoma. Kaminski advises the patients to be aware of this new type of lymphoma treatment and talk it over with their oncologists. We have to be open to all new discoveries and if they prove to be good, embrace them.